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Abstract Health technology assessment (HTA) was developed in the 1970s and
1980s to facilitate decision making on the desirability of new biomedical technol-
ogies. Since then, many of the standard tools and methods of HTA have been
criticized for their implicit normativity. At the same time research into the character
of technology in practice has motivated philosophers, sociologists and anthropol-
ogists to criticize the traditional view of technology as a neutral instrument designed
to perform a specific function. Such research suggests that the tools and methods of
more traditional forms of HTA are often inspired by an ‘instrumentalist’ conception
of technology that does not fit the way technology actually works. This paper
explores this hypothesis for a specific case: the assessments and deliberations
leading to the introduction of breast cancer screening in the Netherlands. After
reconstructing this history of HTA ‘in the making’ the stepwise model of HTA that
emerged during the process is discussed. This model was rooted indeed in an
instrumentalist conception of technology. However, a more detailed reconstruction
of several episodes from this history reveals how the actors already experienced the
inadequacy of some of the instrumentalist presuppositions. The historical case thus
shows how an instrumentalist conception of technology may result in implicit
normative effects. The paper concludes that an instrumentalist view of technology is
not a good starting point for HTA and briefly suggests how the fit between HTA
methods and the actual character of technology in practice might be improved.
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Introduction
The rapid growth of technological possibilities in health care is accompanied by a
growing need to determine an emerging technology’s desirability before it is
introduced in the health care system. In the 1970s and 1980s Health Technology
Assessment (HTA) was developed as a way to facilitate collective decision making
on the desirability of new biomedical technologies. The birth of HTA is often dated
in 1975, when the American Congress asked its Office for Technology Assessment
(OTA) which justification was necessary to introduce a new medical technology [4,
p. 2; 6, p. 276]. The report, published in 1976, defined technology assessment quite
broadly as: ‘‘a comprehensive form of policy research that examines the short- and
long-term social consequences (e.g. societal, economic, ethical, legal) of the
application or use of technology’’ [33, p. 45].
From the start HTA has had a complicated relationship with ethics and politics—
or with normativity in general [6, 36, 38, 44]. Some advocates approach HTA as the
first step in a two-tiered process (e.g. [40]). In this conception HTA researchers
collect evidence about the probable consequences of a technology (‘assessment’),
which is subsequently weighed by ethicists or political actors (‘appraisal’). Others
argue, in contrast, that HTA-reports should pass judgment on the value of a
technology itself (e.g. [58]).
Although not everyone agrees that HTA should include normative conclusions as
to what is or is not desirable, many authors have criticized the idea that factual
assessment and normative appraisal can be clearly separated. They point out that
HTA methods to collect evidence on a technology’s performance are inevitably
imbued with values. Therefore, its results are not as neutral as often purported [21,
27, 30, 36, 38, 43, 44, 58]. For example, the selection of consequences to take into
account, as well as the choice of specific outcome measures to assess them both
have a normative impact. The interpretation of apparently technical concepts like
‘efficacy’, ‘safety’ and ‘cost-effectiveness’ rests on evaluative choices; the same
goes for ‘health,’ ‘disease’, ‘disability’ or ‘quality of life’ [20, 21, 32, 38].
At about the same time philosophers, sociologists and anthropologists concep-
tually and empirically investigated the character of technology. They criticized the
common idea that technology is a neutral instrument designed to perform a specific
function. Some argued that technology is a complex phenomenon, consisting of
material, social and organizational elements [1, 26]. Others pointed out that, because
of this complexity, technology does much more than it is intended to do [5, 31].
Many of these effects are indirect: technology mediates our experience of reality
and the options for action we perceive [22, 62]. Such analyses imply that the effects
of a novel technology are much more difficult to foresee than the instrumentalist
view of technology suggests.
This conceptual and empirical work on the character of technology in practice
seems to suggest that tools and methods of traditional forms of HTA may be
problematic partly because they are based on an instrumentalist conception of
technology that fits badly with the workings of technology in practice. In this paper,
I will explore this hypothesis by reconstructing and discussing an early endeavor to
systematically assess a technology’s desirability: the assessments and deliberations
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preceding the introduction of breast cancer screening in the Netherlands in the
1970s and 1980s. Although these activities were not yet labelled as ‘HTA’, the case
is interesting precisely because it shows the ideal of HTA ‘in the making’ and set
the stage for subsequent HTA activities.1 In this period a model of HTA emerged
that was widely used, both in the Netherlands and abroad, for many years (as is
visible, for example, in the special issue on the history of HTA in the International
Journal of Technology Assessment in Health Care 25, Supplement 1, 2009).
First I will reconstruct the processes preceding the decision to introduce a nation
wide program for breast cancer screening in the Netherlands. This reconstruction is
based on a systematic survey of: (1) the relevant advisory reports and policy
documents in the years 1968–2005; (2) the minutes of Dutch Parliament in the years
1970–1995; (3) the medical professional journals Nederlands Tijdschrift voor
Geneeskunde (1960–2005) and Medisch Contact (1960–2005); and (4) opinion
articles on breast cancer screening in the Dutch national newspapers (1960–2005).
Subsequently I will reconstruct the stepwise model of HTA that emerged during the
process and analyze how this model was based on an instrumentalist conception of
technology. I will proceed then with a more detailed discussion of three episodes.
These episodes illustrate how the actors during the process were already confronted
with or became aware of unanticipated effects, and how this in some cases led to
adjustments in the HTA procedures. The historical analysis enables me, in the end,
to argue how and why an instrumentalist conception of technology is not a good
starting point for HTA. I will conclude with some suggestions for improving the fit
between HTA methods and the actual character of technology in practice.
Debating the Desirability of Breast Cancer Screening: HTA in the Making
The history of breast cancer screening starts in the 1950’s and 1960’s, when in
France and the USA a radiological device for diagnosing breast diseases was
developed [19]. It was noticed soon that this device, called mammography, detected
lesions that were not found by palpation (the current diagnostic standard).
Moreover, these lesions were often smaller than those detected by palpation.
Mammography thus seemed to offer promising possibilities for earlier diagnosis of
breast cancer, which in turn might improve curability and survival rates.
When an American study showed that mammographic screening might reduce
breast cancer mortality by 30% concerned scientists in the Netherlands set up
several pilot projects to corroborate the effectiveness of mammographic screening
in a Dutch setting. In 1975 projects started in Nijmegen, Utrecht and Leiden. The
Leiden project was meant as a pilot project offering a novel health care service and
lasted only 1 year. The projects in Nijmegen and Utrecht had scientific goals and
were designed as case control studies.
In 1977 the Dutch Minister of Health asked the Health Council to report on the
desirability and acceptability of a national breast cancer screening program. The
1 Banta and Oortwijn [3], writing the history of HTA in the Netherlands, identify the first Dutch HTA
reports as of 1988 and 1989, but they focus on the reports and activities explicitly labeled as HTA.
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committee established by the Health Council consisted of a number of medical
professionals and a sociologist; a psychologist was added later on. The committee
soon concluded that the available evidence on the effectiveness of mammographic
screening was limited and decided to wait for the results of the pilot projects in
Utrecht and Nijmegen before formulating its advice. Since the Dutch projects were
case control studies and thus liable to bias, results from randomised clinical trials
(RCT’s) in other countries were taken into account as well. The Health Council’s
committee issued two interim reports and a final report [15–17].
When the second interim report cautiously judged the available evidence for
effectiveness of screening as promising, the Minister of Health ordered an
independent study of the cost effectiveness of such a screening program—actually
the first such a study to be ordered by Dutch government. This study, written by the
Institute for health Technology Assessment of Erasmus University, was published in
1990 [9]. The study not only calculated the costs per saved life year; it also used
QALY’s (Quality Adjusted Life Years), a relatively new tool to take into account
effects of screening on the screened individual’s wellbeing.
To sum up, although the label ‘HTA’ was not used yet, mammographic breast
cancer screening was the first health care technology in the Netherlands to be
systematically assessed for its efficacy, safety, cost effectiveness and impact on
quality of life, with the explicit aim to inform and facilitate political decision
making. When the experts judged that the performance of mammographic screening
on these items was acceptable, the Minister proposed to gradually introduce breast
cancer screening for women aged 50–69 on a national scale, as the Health Council
had advised. The Dutch Health Insurance Council was asked for advice on the
financial and organizational aspects of such a screening program. It proposed to
make screening free for participants and to organize it in a centralized way, closely
resembling the set up of the pilot projects [63]. These suggestions were accepted by
the Minister.
The desirability of the screening program was not only discussed in scientific
reports, however. It was also the subject of public and political debate. Both during
the preparatory phase and immediately after the Health Council published its final
report, a small group of opponents voiced criticism. Most of these critics had a
background in social science or social medicine. They wrote pieces in newspapers
and medical journals arguing that a screening program would seriously contribute to
medicalization [8, 41, 45–50, 61]. In response, others (often investigators of the
pilot projects or members of the Health Council’s committee) stressed the
advantages of breast cancer screening and the evidence for the positive effects of
such a program [10, 12, 37, 54].
The first extensive parliamentary debate took place in 1991, when the
Parliamentary Commission on Health Care discussed the proposed national breast
cancer screening program with the Minister of Health. Although no one completely
opposed the screening program, several members of parliament took up criticism
voiced earlier in newspapers and journals. Some suggested that if women were
really to decide autonomously about their participation, the invitational letter should
explicitly mention the uncertainties and potentially negative effects of screening.
Others questioned the justification of the proposed age limits. And some argued that
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the program might lead to overdiagnosis, overtreatment, and thus to unnecessary
medicalization [51].
In his response, the Minister first pointed out that many of the potential negative
effects of screening had been taken into account in the cost effectiveness study, in
particular by the use of QALY’s [52]. In a second debate between the Minister and
the Parliamentary Commission on Health Care, in 1993, the Minister recognized,
however, that there might be a tension between voluntary participation and the need
for high participation rates. He promised to guarantee (1) respect for the freedom of
choice and personal life of the women involved (by giving even handed
information); (2) equal access (again by giving good information and by making
participation free); and (3) a high quality of care (by installing an extensive
monitoring system) [53, pp. 13–14, 18].
Thus, between 1989 and 1995 breast cancer screening was gradually introduced
in all regions of the Netherlands. Since 1995, all Dutch women between 50 and 69
have been invited for breast cancer screening every 2 years. Effectiveness,
efficiency and quality of care of the screening program continued to be monitored
by an independent scientific committee. Participation rates (and thus apparent
acceptance by the target group) slowly increased from about 75% in 1990 to 82% in
2007 [25].
Since then, public and political debate on breast cancer screening rekindled on
two occasions. The first debate took place when practice with regard to the upper
age limit was changed. Although the upper age limit was set at 69, initially
participants reaching the age of 70 could continue screening if they liked to. In 1992
the Health Insurance Council announced that from now on the age limit would be
strictly kept. This decision was justified mainly with budgetary reasons, but doubts
about effectiveness and worries about the impact of screening on older women’s
lives were also mentioned [56, p. 139]. The decision initiated a heated debate, in
which representatives of associations for the elderly claimed a right to be screened
and accused the Council of age discrimination and paternalism. Medical profes-
sionals supported their claims (e.g. [55]). In the end, the upper age limit was
increased to 75 years in 1998 when new evidence suggested that screening this age
group could be effective after all [57].
A second surge of debate occurred when the Cochrane Collaboration in 2001
published a critical metareview of the available evidence for the effectiveness of
breast cancer screening. The authors concluded that this effectiveness was doubtful
and that screening might even produce harm, in terms of overdiagnosis and
overtreatment [34, 35]. This led to a renewed public exchange of arguments pro and
contra screening, in which the strengths and weaknesses of the scientific methods to
establish effectiveness were also subjected to debate. Some critics argued once more
that the information given to women when invited for screening was too biased to
enable autonomous decision making [59]. The debate subsided after a Health
Council committee, hastily asked by the Minister of Health to advise whether the
Dutch program should be adjusted or even abolished in view of the Cochrane
review, concluded that there was no need to do so. Effectiveness might be somewhat
lower than previously expected, but it was sufficient to justify a national screening
programme [18].
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Emerging HTA and Its Instrumentalist Presuppositions
In effect, then, mammographic breast cancer screening was the first health care
technology in the Netherlands to be subjected to a more or less systematic
assessment, with the aim to inform and facilitate political decision making. In the
process a model of HTA emerged that now seems quite familiar and self-evident
because since then it has been used widely, both in the Netherlands and in other
countries. What is interesting about the historical case discussed here is that it shows
the gradual ‘birth’ of this widespread model in the Dutch context.2 In reconstruc-
tion, the process consisted of four stages, each considering a specific aspect of
mammographic screening:
1. Health gains
2. Cost-effectiveness
3. Organizational conditions
4. Ethical considerations (like justice, autonomy, screening rights, medicalization)
The first three stages occurred in a chronological chain: the next stage was
initiated only when the results of the preceding one appeared to be sufficiently
positive. They were also linked to a clear division of roles and responsibilities. The
Ministry of Health delegated the first three stages to scientific experts: the Health
Council, independent economic scientists and the Health Insurance Council
respectively. In contrast, the ethical considerations were (implicitly) left to public
and political debate. They occasionally popped up during the process, with a clear
increase in the final stages of decision making.
This procedure seems to have been inspired by an implicit instrumentalist view
of technology in several respects. Such a view perceives technology as a material
device that is designed to perform a specific function. It is an instrument (‘just a
means’) to realize a specific goal; the instrument itself is value neutral. This view
has been widespread in Western thinking [14, 62], so it is not surprising that it
influenced ideas and tools for HTA. What is the task of (H)TA from an
instrumentalist perspective? If technology is a device designed to fulfil a specific
function, the first question is of course whether the proposed device is indeed
capable to fulfil this function. Assessments should ask, then, to what extent the
device realizes the intended effect. The goal (the intended effect) itself is supposed
to be clear and is taken for granted for the time being, as is the device’s actual
design.
Seen this way, it makes sense to separate the factual assessment of a device’s
performance from the normative evaluation of the intended goal. Such a separation
is clearly implied by the split between stages 1–3 and stage 4 in the mammographic
screening case. Whereas establishing the facts was considered a task for scientific
experts, evaluating goals was assigned to the political domain. The experts involved
in the mammographic screening research endorsed this view. In its final report, the
2 This does not mean, of course, that the Dutch were the only ones, or even the first to ‘invent’ this
model. Nor does it mean that other countries imported the Dutch model. In all likelihood, the concept of
technology assessment in health care was picked up by several countries at the same time, each importing
insights from elsewhere and giving it a national flavor at the same time.
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Health Council deliberately refrained from statements about the desirability of a
national screening program, because this was considered a political issue [17, cover
letter p. 2]. In a similar vein, the authors of the cost-effectiveness study stated that
considerations other than cost-effectiveness could ‘‘of course’’ play a large role in
the political deliberations [9, p. 7].
The instrumentalist view is also clearly visible in the set up of the first assessment
stage. Mammography was approached as a material device designed to diagnose
women with asymptomatic breast cancer, in order to increase the life expectancy of
these women. To decide about the desirability of this device, the uncertainty with
regard to its performance had to be reduced. Did it diagnose sufficient asymptomatic
cancers, and did this early diagnosis lead to increased survival? The pilot projects
and the report of the Health Council thus initially were set up to produce factual
evidence on the actual magnitude of the intended effect only.3 The only additional
effect that was taken into account was the potential causation of new tumours
resulting from the radiation necessary to make the mammograms—a side effect, that
is, that would directly detract from the intended effect. In the second and third stage
of the assessment the financial and organizational efforts needed to realize the
intended effect were charted, to enable an informed comparison with potential
alternatives.
The HTA procedure developed in this historical episode thus was driven by
instrumentalist presuppositions. This is visible in particular in (1) the separation of
assessment of facts by experts from the deliberation on desirability by political
actors and (2) the exclusive focus on the intended effect (i.e. mortality reduction).
However, a closer look at the historical episode shows that the actors involved also
encountered problems resulting from limitations and shortcomings of the instru-
mentalist view. Some of these problems were diagnosed already by the actors
themselves, resulting in modifications of the assessment procedure or other attempts
to compensate for the procedure’s weaknesses. Other problems can be identified
with the benefit of hindsight, suggesting a need for further modification. Thus, while
trying to invent a systematic procedure to assess mammographic screening, the
actors involved learned important lessons about the lack of fit between an
instrumentalist view of technology and the way technology works in practice. In the
next part of this paper, I point out how difficulties arose with respect to three
presuppositions inspired by an instrumentalist view of technology:
(1) Technology is a means to realize intended effects;
(2) Technology is a material device;
(3) Morality may influence technology, but technology does not influence
morality.
3 Here, an interesting difference between TA and HTA can be observed. Whereas HTA usually focuses at
intended outcomes, TA from the start has tried to include unintended side effects, like environmental
damage. Part of the explanation may be that most HTA is driven by financial motives and thus has a more
narrow scope (the need to select the most cost-efficient technologies). In addition, the side effects of
medical technology that are visible and feared most are the ones that directly counter the intended goal by
causing infirmity or death. Such side effects can be assessed using the outcome measure that is also used
to measure the intended effect.
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Lesson 1: Technology Does More Than It is Intended To Do
As described above, the first publications on mammography present it as a tool to
improve the prognosis of women with asymptomatic breast cancer. The actors
involved in the assessment process are aware, however, that measuring improved
prognosis is rather complicated. Counting cases of early detection does not suffice;
the screening program is successful only if subsequent treatment is effective and
results in prolonged healthy lives. Therefore the outcome measures proposed at first
are 10 years—survival and mortality rates. However, because an increase of
10 years survival rates without a concurrent mortality reduction is considered
undesirable, reduction of breast cancer mortality quickly becomes the central
measure of effectiveness. The pilot projects in Utrecht and Nijmegen are explicitly
set up to investigate to what extent mammographic screening reduces breast cancer
mortality. The Health Council in its first report (1981) affirms this choice: this is the
intended effect of mammographic screening and it should be the central focus of the
assessment procedure.
The actors gradually become aware, however, that mammographic screening
does more than it was intended to do and that these additional effects may also be
relevant when assessing the technology. The Health Council’s 1984 report, for
example, mentions ‘quality of life’ as an additional outcome measure for the
effectiveness of mammographic screening:
Therapeutic effectiveness in the above is translated as reduced breast cancer
mortality. However, this is not the only measure of effectiveness. One could
also think of an improved quality of life. It is important to point at the so
called breast saving surgery techniques that have gained ground in the
treatment of early stage breast cancer lately. [16, p. 25]
This development of breast saving surgery techniques was actually spurred by the
increasing number of ‘pre-clinical’ tumors becoming available as a result of
screening [13, p. 95]. The novel surgery techniques were thus co-produced by
mammographic screening, resulting in an unforeseen (and up to then unintended)
effect. Decreased mutilation and increased wellbeing of patients now emerged as a
potential additional goal of breast cancer screening, next to mortality reduction.
Thus, the assessors’ initial focus on the intended effect only started to look too
narrow. The concept of quality of life was proposed to broaden the scope of the
assessment, to allow different types of presumably positive effects of screening to
become visible. Although such effects were not explicitly intended at the start of the
projects, the Health Council appears to have been willing to include this novel
measure in the assessment. However, the investigators of the two Dutch pilot
projects did not include ‘quality of life’ as an additional measure of effectiveness,
presumably because they did not want to change the design of their long term
studies.
It is only in the cost-effectiveness study (1990), therefore, that quality of life first
appears as a measure of effectiveness. The authors of this report motivate the
introduction of the concept in a way that is very different from the Health Council’s
earlier suggestion:
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… next to mortality reduction, inevitably undesirable effects will occur. An
undesirable effect is, for example, anxiety in women who are referred for
further diagnostics and who in the end appear not to have breast cancer (the
false positives (…)). Another undesirable effect is that a number of women
now know they have breast cancer whereas for some of them the prognosis
won’t improve. (…) Weighing the amount of desired and undesired effects on
the one hand and the expected costs and reduced expenses on the other is
necessary. [9, p. 6]
Here ‘quality of life’ is not meant to measure additional positive effects of
screening; on the contrary, it is a measure for any impact (both desirable and
undesirable) screening might have on the lives of individual participants.
Thus, the actors involved in the assessment of breast cancer screening gradually
realized that mammographic screening may have significant impacts besides the
intended increase in life expectancy, and that these effects, moreover, need not
always be positive. Voices from the public debate (on breast cancer screening, but
also on other medical technologies) may have played a role here. The introduction
of ‘quality of life’ was an attempt to accommodate a broader array of effects, in a
way that apparently enabled a sensible comparison of these effects. This history
corroborates the argument made by Armstrong and Caldwell, who claim that the
emergence of ‘quality of life’ in the 1970s and 1980s among others expressed a
general discomfort regarding the human costs of technological interventions [2,
p. 36]. In the Dutch case, the concept helped to weigh the various effects of
mammographic screening. The desire to include patients’ perspectives (often
mentioned as a justification to include quality of life) apparently hardly played a
role.
It is clear from the cost-effectiveness report how the researchers struggled with
the operationalization of ‘quality of life’ [9, pp. 113–119]. What should or should
not be included? How to operationalize the more subjective types of impacts? And
how to compare different types of impacts? Interestingly, the questionnaires to
assess quality of life impacts were not filled out by women participating in the pilot
projects, because the questions were considered too complex for these participants.
Instead, ‘stand ins’ like economists and medical professionals involved in cancer
screening and care acted as respondents. The first were considered to be more used
to this type of questionnaire, and the latter were supposed to have a reliable view of
how breast cancer may affect women’s lives. Since then, struggles have continued,
leading to a proliferation of instruments measuring quality of life, most of which do
involve patients (or healthy subjects) as respondents. Quality of life, in addition to
mortality reduction, has become a widely accepted dimension for assessing the
impact of novel medical technologies. However, controversy over the tools to
measure it persists.
Notwithstanding these difficulties, the history of assessing breast cancer
screening shows why HTA should not focus on a technology’s intended effect
only. Technology does more than it is intended to do, both directly and indirectly.
As for the direct effects, screening may increase one’s life expectancy and decrease
wellbeing at the same time. Focusing exclusively on the intended (hoped for) effects
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inevitably biases the assessment and leads to (avoidable) implicit normativity of the
results. Including a broad array of potential effects is important for even handed
decision making on the desirability of a novel technology. Unintended effects are, of
course, difficult to foresee. This is even truer for indirect effects, like the improved
surgery techniques resulting from the emergence of early diagnostics. Good HTA
should nonetheless try to anticipate and include such effects, both at the start and on
the way, as the Dutch assessors tried to do.
Lesson 2: Technology is More Than a Material Device
As described above, the reduction of breast cancer mortality by mammographic
screening not only requires a well functioning mammographic device, but also an
effective therapeutic follow up. Breast cancer screening has, then, clear social and
organizational conditions from the start. However, at first both the researchers and
the political actors involved approach mammographic screening as a material
device that processes input (asymptomatic women) to deliver a specific output
(mortality reduction). The pilot projects are presented as a means to find out how
effective this new diagnostic technology will be when applied to asymptomatic
women. Practical conditions like setting age limits and frequency of screening do
get some attention, but only in relation to the question how to increase the
screening’s effectiveness. It is interesting to see how the actors in the Dutch
screening assessment seem to have become gradually aware of the importance of
social and organizational conditions; an awareness that in the end led to a strict
regulation of the national screening program and even to a law on population
screening.
When the results of the pilot projects seem sufficiently promising to warrant
serious consideration of a nation-wide screening program, the researchers start
pointing out that the organizational setting of screening is crucial. The positive
results can be repeated only, they state, when the national program is conducted in a
way similar to the pilot projects. The Health Council agrees. In its second report it
states:
The committee emphasizes that a potential screening program will succeed or
fail depending on the way the introduction and design are organized. (…)
Guarantees are needed for the quality of the work of participating centers
(diagnostics, treatment and counseling of the women involved). In this respect
it is important that strict protocols are kept. A newly instituted center of
reference might serve quality control as well. [16, p. 28]
Both the scientific and the political actors thus gradually became aware that
mammography is more than a material device and that breast cancer screening
requires more than the distribution of mammography devices. As a result, they
concluded that a national screening program should be as similar to the pilot
projects as possible. The awareness that organizational conditions are crucial in
realizing a certain effect motivated the Health Council’s advice to centralize the
organization of screening and make it a uniform practice. Moreover, since the pilot
projects were designed as a separate, autonomous service, situated between GP’s
Health Care Anal (2012) 20:84–102 93
123
and hospitals, the national program also became a separate service next to primary
and secondary health care. Thus, because the sociotechnical character of mammo-
graphic screening came into the picture relatively late, the organizational choices of
the scientific pilot project became indicative for the organization of the national
program. As one critic stated, when the committee developed a refined constellation
of protocols and procedures for national screening practice, it was actually ‘‘trying
to approach the conditions of scientific research’’ [8, pp. 475–476]. This blocked
serious consideration of alternative options. Even the question whether or not all
actors agreed with the proposed division of roles and responsibilities was hardly
discussed.
The growing awareness of the social conditions for realizing the aimed for
mortality reduction also influenced the approach of and the role ascribed to female
participants. In its final report the Health Council explicitly mentions a high
participation rate as a condition for attaining the aimed for effect: ‘‘The committee
emphasizes the importance of a maximal participation in screening for breast
cancer. If the participation rate is too low, the aimed for mortality reduction on the
population level may also become too low’’ [17, pp. 39–40, see also 50–54].
Recommendations were formulated to make screening as accessible as possible: the
invitational system should function well, screening should be affordable, the
location of screening centers should be accessible, counseling should be available,
and education should be as persuasive as possible: ‘‘Careful education of the female
population is necessary. Research into the effectiveness of education with regard to
the participation of the women involved in screening is necessary’’ [17, p. 72]. Here,
the need for a high participation rate to achieve the aimed for effects actually led to
a neglect of a potentially conflicting value: the autonomy of participants.
The implicit tension between effectiveness and women’s autonomy came to the
fore once more in 1991, when the Minister of Health in a letter to the Health
Insurance Council in 1991 simply states that invitations, leaflets and campaigning
material should contribute to high participation rates as well as enable considered
choices by the women in the target group [51, p. 11]. In the parliamentary debates
on screening, however, MP’s stressed that autonomy was the most important value.
This position in the end was confirmed by the Minister in a memo from 1993,
stating that information on screening should include negative aspects of screening,
even if this would lead to a decrease of participation rates [53, pp. 13–14].
This episode shows how the implicit view that technology is a material device led
the assessors of mammographic screening to neglect the social and organizational
elements of this technological practice for a long time. In the end they did stress the
importance of social and organizational conditions, but because the outcomes of the
assessment by then were quite promising, this did not result in discussion on the
pros and cons of the specific design of the screening practice in the pilot studies. On
the contrary, the practice investigated in the pilot projects now was put forward as
the most desirable. Moreover, these conditions were approached only in terms of
effectiveness; issues of feasibility and desirability did not come to the fore.
These episodes show once more how the view that technology assessment is
about the intended effects of a material device may lead to implicit normative
effects of the assessment procedure, in this case with regard to the social and
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organizational conditions. It tends to limit or even close off the space to discuss the
pros and cons of alternative designs of the practice at hand. Moreover, it may lead to
roles for both professionals and lay users that are not acceptable to them or that
severely diminish the realization of alternative values (like autonomy). Conceiving
novel technology in terms of a sociotechnical practice might help to avoid this
implicit normativity by including such social and organizational aspects in the
assessment procedures right from the start.
Lesson 3: Technology Does Affect Morality
The third and last presupposition of the assessment procedure for mammographic
screening I want to discuss here is that the development of mammographic
screening itself would not affect morality. As pointed out above, the instrumental
view of technology implies that humans can first set goals and then decide whatever
technology serves their goals best. In the case of mammographic screening the
starting point was that health is an important value to many people. The assessment,
then, need not focus at the goal aimed for, but only at the question to what extent
screening would realize this goal. Such reasoning presupposes, however, that the
meaning of ‘health’ is clear, widely accepted and stable. The history of the HTA
process and the resulting screening practice show, however, that both the meaning
of and the weight assigned to ‘health’, changed as a result of the technology
development. Since this is a long term process, it is easier to discern with the benefit
of hindsight. The actors involved in the assessment touched on these issues only
incidentally.
First, the meaning of the value ‘health’ seems to have shifted. Interestingly, some
actors involved in the process actually anticipated this shift. One of the first Dutch
professional publications on early detection of cancer pointed out that ‘health’ was
usually conceived of as not having to notice your body. The authors explicitly
asked:
Is it desirable indeed to ask people’s attention for their own body as a source
of disease time and again? Or would a healthy life rather consist in living
without having to worry about one’s breasts, intestinal tract or stomach?
[24, p. 67]
The issue was both conceptual (a shift might occur in the way ‘health’ is generally
interpreted) and psychological (this conceptual shift might have impact on people’s
lived experience). Typically, the authors of this report declared they were not
competent to address such questions. They did not indicate who would be either.
Not surprisingly, then, the issue was hardly taken into consideration in the
subsequent assessment and deliberation processes. As discussed earlier the scientists
first defined health exclusively in terms of survival and later also in terms of quality
of life. Considerations on the impact of screening on views and experiences of
health incidentally reappeared in newspaper contributions arguing against screen-
ing. They were also briefly mentioned in the parliamentary debates. However, since
empirical evidence for such ‘soft impacts’ [7] was absent (and hard to investigate
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anyway), they were easily dismissed in view of the positive evidence for the
effectiveness of screening.
In retrospect it seems nonetheless justified to conclude that the introduction of
breast cancer screening, albeit in conjunction with many other technologies for early
detection of disease, did contribute to a new understanding of what it means to be
healthy or diseased. The long standing view that ‘health’ means absence of
complaints has been exchanged for the view that disease can be a-symptomatic. As
a result, most people now probably accept the view that they can have a disease
without noticing anything. This is actually a generalization of the shift that
mammography brought about earlier in the medical domain. The starting point of
the debates on screening was, after all, the observation that this technology enabled
doctors to identify lesions in women who had up to then seemed perfectly healthy,
both to themselves and to their doctors.
This novel view of disease and health has brought along new norms as well. On
the one hand, the new technological possibilities have led to new obligations. Now
that it is possible to diagnose a-symptomatic disease, people are expected to subject
themselves to these technologies. Even though Dutch women are not legally
required to participate in the mammographic screening program, those who do not
participate often have to justify their choice. They may even be accused of
irresponsible behavior, especially if they are diagnosed with breast cancer later on.
Participation in screening, that is, has become a social norm.
On the other hand, novel rights have been claimed. At the introduction of a
nation wide program for breast cancer screening the age limits of the target group
were set as 50 and 69 years. Evidence for the effectiveness of screening older
women was thought to be lacking (another example of how the design of the pilot
projects became normative for the national program). As described above, in 1992
the Health Insurance Council (responsible for the funding of the national program)
decided to keep a strict hand at the upper age limit, partly motivated by
overspending. The Council was confronted with an indignant public response from
elderly women as well as medical professionals. They argued that women had a
right to be screened, and that denying this right to a subgroup of women on the basis
of their age amounted to age discrimination [55]. Apparently women above 70 who
had been screened for some years felt that they were denied something valuable.
Of course one may question the legitimacy of this claim. However, just the fact
that it was actually claimed shows that a substantial group of people had come to
perceive screening as a ‘good’ that women are entitled to and that should be
distributed justly. Thus, the screening providers and politicians were confronted
with moral considerations they had not anticipated when assessing and deliberating
the desirability of mammographic screening. As a result they were at a loss: how to
deal with this novel argument?
Interestingly, the issue was approached in a way resembling the original
assessment process: judgment on desirability was postponed pending the production
of evidence on the effectiveness of screening older women. Novel research was
started; in the meantime the age limits were strictly kept. In 1998 a Dutch case
control study claimed to have shown that reduction of mortality for 70–75 years
olds was possible and that screening could significantly improve the quality of life
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of this group. Some actors argued that this evidence was not sufficiently conclusive,
since it was not based on RCT’s and thus could be biased. However, the political
decision makers thought it would be unacceptable to let older women wait any
longer for the outcomes of such (usually very long term) studies [57, p. 1098]. In
this respect, the claim that a moral right was at stake mitigated the standard of
scientific rigor used in the political decision making.
In sum: although the initial assessment procedure was predicated on the
assumption that mammographic screening would not affect the value of health, both
common views of health and disease, as well as related obligations and rights were
affected by the development and introduction of mammographic screening. To be
sure, mammography was not the only source of these changes. The concurrent
emergence of many other technologies for early diagnosis definitely played a role as
well. Overall, this historical episode illustrates how technology and morality
mutually interact. Morality may steer technology development, but technology also
influences morality.
If so, HTA had better acknowledge this mutual interaction. Partly for practical
reasons: if the actors involved reflect on the potential impact of technology on
morality, they will be confronted with unanticipated changes in morality less often.
Another reason is that such changes may affect judgment on the desirability of a
technology. Since it is usually very difficult to withdraw or prohibit a technology
already in use (as the controversy on age limits shows), it makes sense to try to
anticipate an emerging technology’s long term impacts. This presupposes, however,
that HTA discards the assumption that morality is stable and independent from
technology.
Tailoring HTA Methodology to Technology: Some Suggestions
To sum up: the actors involved in the assessment of mammographic screening in the
Netherlands not only developed a general procedure for HTA. In the process of
assessing mammography, they were also confronted with several limitations and
weaknesses of this procedure. With the benefit of hindsight we can trace even more.
These limitations and weaknesses are related to instrumentalist presuppositions
implicit in the assessment procedure. My reconstruction of the case displays how at
various moments a misfit emerged between the instrumentalist presuppositions of
the procedures and the way technology actually works. These misfits produced
implicit normative effects because important considerations were not or only
marginally taken into account. This significantly reduces the moral and political
legitimacy of the judgment on the desirability of mammographic screening—even
though mammographic screening since its introduction has been a widely accepted
technological practice in the Netherlands.
The historical case is interesting because it reminds us that HTA procedures and
tools should fit with the way technology works. This may sound self-evident, but it
is easier said than done. Too many assessments today still resemble the procedure
emerging in this early example. How to tailor HTA methodology to technology,
then? In this section I will summarise the lessons for HTA that can be drawn from
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the case of mammographic screening, while briefly suggesting which tools or
measures might help to avoid the weaknesses from the past.
First, technology does more than it is intended to do: it has a broad array of
effects. Many of them are hard to measure in a quantitative way. Moreover, complex
interactions may occur. As a result, many effects are difficult to foresee. It would be
naı¨ve to suggest that all effects can be anticipated and included in HTA of emerging
technologies. However, one might at least attempt to be as inclusive as possible. A
first step is to engage users, or more generally stakeholders, early in the assessment
process [23, 39, 60]. Including actors with different backgrounds in the assessment
process will help to chart and imagine the wide variety of effects a technology might
have. This helps to reduce unpleasant surprises later on. It also contributes to the
democratic legitimacy of the deliberation process.
To avoid foreclosing or steering of such an inventory, it may be advisable to start
with explorative, qualitative research [28, 29]. This would allow stakeholders to
respond as much as possible from their own perspective and in their own words.
Stakeholders could also be asked to participate in the selection of effects to be
measured and to comment on proposed outcome measures, to ensure these do
justice to the rich meaning of anticipated effects. Scientific research all too often
results in knowledge that only partially covers stakeholders’ considerations. Quality
of life measurement is a case in point.
Furthermore, particular attention needs to be paid to long term and so called
‘soft’ impacts.4 Technology does not only affect our health, environment or safety.
It also influences our (to list just a few) health care practices, roles, responsibilities
and identities. Because such effects usually emerge only gradually and do not lend
themselves for quantitative research, they are easily neglected [7]. Even
stakeholders may not think of them. To remedy this, historical and comparative
analysis could be used as a source of imagination. Earlier examples, ongoing trends
and patterns can help to make us more aware of the soft impacts. In addition, they
can be used to enhance our imagination of what might happen in the future (for an
example see [7]. Historical and sociological insights can be incorporated, for
example, in scenarios of possible futures. These may in turn serve to feed
stakeholders with rich material for their deliberations.
The second lesson from the case discussed above, partly related to first one, is
that technology should not be approached as a device, but as a sociotechnical
practice. This means that the social and organizational conditions for making the
material device work have to be included right from the start of the assessment [39].
The aim here is not to assess how effective they are with regard to the intended
outcome, but to explore additional impacts, for example on the division of roles and
responsibilities of the actors involved. To avoid normative effects resulting from the
experimental design, it might help to experiment with alternative sociotechnical
designs at the same time (for a similar suggestion see [11]. This would enable
comparisons and thus result in informed debate on the acceptability and desirability
of proposed practices.
4 The term ‘soft impact’ has been coined by Tsjalling Swierstra, see http://www.onderzoekinformatie.
nl/nl/oi/nod/onderzoek/OND1337080/.
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Finally, the third lesson is that morality is not a stable phenomenon; it is evolving
and technology is an important driver of this evolution. When assessing and
debating the desirability of an emerging technology one should, then, take into
account the mutual interaction of morality and technology and try to anticipate such
effects. A tool to support this is, again, historical analysis, which could then be used
to construct plausible scenarios that serve as input for public and political debate
[42].
As I indicated above, all this will not suffice to foresee and predict a new
technology’s impact. Technology is a complex phenomenon and so is society, and
the confrontation of the two is bound to produce events and effects no one would
have been able to imagine in advance. If this is true, it makes sense to construct
assessment procedures as flexible as possible. It should be possible to incorporate
unexpected effects or adjust outcome measures later on.
Overall, these lessons and the suggested tools aim to broaden the number and
type of considerations that can be put forward in deliberation and debate on the
desirability of novel biomedical technologies. The underlying thought is that this
both improves the quality of the assessment (since fewer aspects will be neglected)
and enhances the democratic legitimacy of the process (since all views can be
seriously considered). I have hardly paid attention to the division of roles and
responsibilities in the deliberation and decision making processes. Much more
should be said, for example, about the relation between scientific experts, clinicians,
lay people and politicians, but this will have to wait for another occasion.
Conclusion
The tools, methods and procedures for HTA are the evolving products of historical
learning processes. The first attempts to perform HTA in the Netherlands started
with the endeavour to provide decision makers with scientific evidence on the
effectiveness of mammographic screening. The resulting procedure was to a large
extent informed by an instrumentalist view of technology. In the process, the actors
performing and using the results of the assessments were confronted with the
weaknesses and limitations of the instrumentalist view. Technology in practice
acted rather differently from what was anticipated. The case shows how the actors
involved partially responded to these surprises by adjusting their assessment
methods. They learned by doing, inventing and developing HTA along the way.
Today, HTA can pride itself on quite some history in many countries. As a result
those performing HTA need not start from scratch. However, the history of HTA is
not only a source of standard models, tools and methods. It is also a source of
experiences in the workings of technology in practice. HTA could take advantage of
these latter experiences more often, to improve the fit between methodology and
technology. Improving this fit will ultimately contribute to the social and moral
legitimacy of HTA results.
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